To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Overproduction of very lo… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.

Review article
Authors Martin Adiels
Sven-Olof Olofsson
Marja-Riitta Taskinen
Jan Borén
Published in Arteriosclerosis, thrombosis, and vascular biology
Volume 28
Issue 7
Pages 1225-36
ISSN 1524-4636
Publication year 2008
Published at Wallenberg Laboratory
Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 1225-36
Language en
Keywords Antilipemic Agents, therapeutic use, Diabetes Mellitus, Type 2, etiology, metabolism, physiopathology, prevention & control, Disease Progression, Dyslipidemias, blood, drug therapy, metabolism, Fatty Acids, metabolism, Humans, Insulin Resistance, Lipoproteins, VLDL, blood, metabolism, Liver, metabolism, Metabolic Syndrome X, complications, drug therapy, metabolism, physiopathology, Triglycerides, metabolism, Up-Regulation
Subject categories Medical and Health Sciences


Insulin resistance is a key feature of the metabolic syndrome and often progresses to type 2 diabetes. Both insulin resistance and type 2 diabetes are characterized by dyslipidemia, which is an important and common risk factor for cardiovascular disease. Diabetic dyslipidemia is a cluster of potentially atherogenic lipid and lipoprotein abnormalities that are metabolically interrelated. Recent evidence suggests that a fundamental defect is an overproduction of large very low-density lipoprotein (VLDL) particles, which initiates a sequence of lipoprotein changes, resulting in higher levels of remnant particles, smaller LDL, and lower levels of high-density liporotein (HDL) cholesterol. These atherogenic lipid abnormalities precede the diagnosis of type 2 diabetes by several years, and it is thus important to elucidate the mechanisms involved in the overproduction of large VLDL particles. Here, we review the pathophysiology of VLDL biosynthesis and metabolism in the metabolic syndrome. We also review recent research investigating the relation between hepatic accumulation of lipids and insulin resistance, and sources of fatty acids for liver fat and VLDL biosynthesis. Finally, we briefly discuss current treatments for lipid management of dyslipidemia and potential future therapeutic targets.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?